Frost & Sullivan, in collaboration with TimePA, releases "2026 Global Longevity Clinic Medical Intervention Classification and Implementation Guide".

Source: TimePie Research Institute, Sullivan Analysis

The longevity medicine assessment focuses not only on test results at a specific time point but also on long-term changes in an individual's health status. The Guide outlines the assessment logic for the transition from a single test to dynamic tracking, centered on baseline assessment, periodic re-testing, trend analysis, and continuous optimization, providing a basis for risk identification and intervention adjustment.

Source: Publicly available materials, literature search, TimePie Research Institute, Sullivan Analysis

In terms of assessment dimensions, The Guide incorporates traditional clinical indicators, biological age, functional tests, multi-omics data, lifestyle records, and wearable continuous monitoring into a comprehensive interpretation framework. Different tools have varying applicable scenarios and levels of evidence; the assessment results need to be interpreted in conjunction with clinical information and long-term re-testing, and further aligned with management decisions such as continuous observation, supplementary examinations, intervention adjustments, or referral.

Source: Publicly available materials, literature search, TimePie Research Institute, Sullivan Analysis

The Guide outlines the research foundation, application boundaries, and maturity of major intervention directions for long-term health management interventions, clinical medical interventions, and cutting-edge exploratory technologies. Different technologies exist at different evidence stages; mechanism research, early human studies, and clinical efficacy validation need to be understood separately, and basic research findings cannot directly be equated with routine clinical application basis.

In terms of evaluation methods, The Guide, in combination with the type of study and the GRADE evidence certainty framework, focuses on bias risk, result consistency, directness of evidence, accuracy of results, and publication bias. For cutting-edge interventions, it further proposes the safety governance chain for technology attribute identification, access review, clinical delivery, and continuous responsibility, incorporating risk-benefit assessment, informed consent, dynamic monitoring, and long-term follow-up into application considerations.

Source: Publicly available materials, literature search, TimePie Research Institute, Sullivan Analysis

As the global population ages, the demand for longevity medicine services is gradually shifting from appearance rejuvenation and single-item health improvement to functional maintenance, chronic disease risk management, and extension of healthy life expectancy. Data from The Guide show that in 2025, the population aged 65 and above in China reached 223.7 million, accounting for 15.9% of the total population; this large elderly population provides a sustained basis for ongoing demand for health assessment, disease prevention, functional maintenance, and long-term health management.

Meanwhile, the payment customer base for longevity medicine is further expanding. In addition to the traditional elderly group, the middle-class group engaged in career and family responsibilities, as well as the younger group that places greater emphasis on early prevention and lifestyle management, are also developing differentiated demands. Longevity medicine services are extending from single-test or treatment to comprehensive assessment, continuous intervention, and long-term health management, and market demand is expanding to a broader range of populations and service scenarios.

Source: Publicly available materials, government official website, Sullivan Analysis

The global longevity medicine industry is gradually forming a development pattern with regional characteristics. The overseas market is represented by the United States, which, relying on biotech innovation, research institutions, and long-term capital support, continues to invest in emerging areas such as cell reprogramming and aging mechanism intervention; in China, it leverages the medical service system, the health consumption market, and industrialization capabilities to promote the transformation of related technologies into detection and assessment, health management, and medical service scenarios.

From an investment perspective, overseas capital emphasizes technology platforms, long-term research and development, and pharmaceutical company collaboration; Chinese investment, on the other hand, is more closely aligned with health needs, medical resources, and commercial applications. Different capital pathways reflect differences in technology maturity and market conditions; industry development requires both research investment and clinical validation, resource integration, and continuous commercialization capabilities.

Source: Publicly available materials, company official website, literature search, Sullivan Analysis

The Guide divides the longevity medicine industrial chain into upstream raw material supply and longevity detection, midstream product manufacturing and data assessment, and downstream major links such as longevity clinics. The upstream provides raw materials and detection infrastructure; the midstream promotes the conversion of products and data capabilities; the downstream connects end-user needs through medical assessment, intervention implementation, and continuous management, forming a multi-link coordinated service system.

As the industry evolves from emerging exploration to standardized application, the focus of competition gradually extends to technology validation, data integration, and service delivery capabilities. The Guide further points out that clinical validation, regulatory standards, and the integration of consumer healthcare and serious healthcare will influence the industry's long-term development direction. Institutions need to strengthen continuous follow-up and effect evaluation on the basis of compliance and evidence, and promote the closer connection between technology, products, and medical services.

Source: Publicly available materials, company official website, Sullivan Analysis

The transition of longevity medicine from research to medical services requires the establishment of a continuous, clear, and executable delivery system. The Guide outlines the capacity building requirements for longevity clinics, focusing on assessment and intervention configuration, personnel positions, operational foundation, medical safety, and standardized processes, and combines the existing foundations of beauty medical institutions, health check-up institutions, and traditional medical institutions to analyze the transformation paths of different types of institutions.

At the service implementation level, The Guide specifies responsible positions, core tasks, and deliverable outcomes across six steps: service reservation, initial risk screening, initial consultation assessment, result integration, plan execution, and iterative re-testing. The standardized process provides a foundation for service quality and risk management, while individualized management adjusts the plan based on risk priority, stage goals, and re-test results, enabling assessment and intervention to form a continuous and connected long-term management process.

Source: Publicly available materials, literature search, TimePie Research Institute, Sullivan Analysis